Showing 4931-4940 of 6770 results for "".
- Upadacitinib Shows Superior Skin Clearance in Head and Neck Atopic Dermatitis Compared to Dupilumabhttps://practicaldermatology.com/news/Upadacitinib-Shows-Superior-Skin-Clearance-Head-Neck-Atopic-Dermatitis-Compared-Dupilumab/2471639/A numerically higher proportion of patients receiving upadacitinib achieved Eczema Area and Severity Index (EASI) 75/90/100 in the head and neck as early as 2 weeks after treatment was initiated compared with those receiving dupilumab in new Level Up study data present
- New Revenue Cycle Management Service Unveiledhttps://practicaldermatology.com/news/New-Revenue-Cycle-Management-Service-Unveiled/2471638/A new solution to alleviate the challenges posed by insurance claim denials and make it easier for providers to salvage denied claims and increase their reimbursement was on display at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, as Nextech previewed the late
- Charlotte Dermatology, DOCS Dermatology Group Partner, With PGP as Advisorhttps://practicaldermatology.com/news/Charlotte-Dermatology-DOCS-Dermatology-Group-Partner-With-PGP-Advisor/2471624/Physician Growth Partners (PGP) announced it recently advised Charlotte Dermatology on its partnership with DOCS Dermatology Group (backed by SkyKnight Capital). Founded in 1939, Charlotte Dermatology is one of the longest-standing and most trusted dermatology practices in the Greater Char
- Further Positive Delgocitinib Data Presented at AADhttps://practicaldermatology.com/news/Further-Positive-Delgocitinib-Data-Presented-AAD/2471609/Late-breaking data presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showcased responses in a subgroup of patients from the DELTA 1 and Delta 2 trials on lebrikizumab for chronic hand eczema. Alongside this presentation, new systemic exposure
- New Baricitinib AA Data for Adolescents Could Be 'Game-Changing'https://practicaldermatology.com/news/New-Baricitinib-AA-Data-Adolescents-Could-Be-Game-Changing/2471600/Patients ages 12 to under 18 with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes at Week 36 in the Phase 3 BRAVE-AA-PEDS study, presented as a late-breaker at the 202
- 3-Year Results: Sustained Psoriasis Treatment Goals Achieved with Risankizumabhttps://practicaldermatology.com/news/3-year-results-sustained-psoriasis-treatment-goals-achieved-with-risankizumab/2471578/New research presented at the 2025 American Academy of Dermatology Annual Meeting showed long-term treatment with risankizumab resulted in sustained skin clearance for most patients with moderate to severe plaque psoriasis. Resear
- Novel TYK2 Inhibitor Shows Promising Results in Phase 2 Trials for PsOhttps://practicaldermatology.com/news/Novel-TYK2-Inhibitor-Shows-Promising-Results-Phase-2-Trials-PsO/2471545/The TYK2 inhibitor ESK-001 has shown promising safety and efficacy in long-term Phase 2 trials for moderate-to-severe plaque psoriasis, Andrew Blauvelt, MD, FAAD, said in a late-breaking research presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.
- Get In First: A Derm's Case for Early Psoriasis Treatmenthttps://practicaldermatology.com/news/from-aad-2025-a-case-for-early-psoriasis-treatment/2471544/Addressing psoriasis early in its course may lead to prolonged remission and better outcomes, and dermatologists should take note, according to a presentation at the 2025 American Academy of Dermatology Annual Meeting in Orlando.
- Almirall Presents Early-Stage Pipeline Progress for Tirbanibulinhttps://practicaldermatology.com/news/Almirall-Presents-Early-Stage-Pipeline-Progress-Tirbanibulin/2471540/Almirall, S.A. presented five scientific posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, including new data on tirbanibulin, a topical treatment for actinic keratosis (AK), and progress of its early-stage asset LAD191, a high-affinity monoclonal antib
- 2-Year Data: Bimekizumab Can Eliminate Draining Tunnels in HShttps://practicaldermatology.com/news/2-Year-Data-Bimekizumab-Can-Eliminate-Draining-Tunnels-HS/2471535/Two-year data from the BE HEARD trials for bimekizumab-bkzx (BIMZELX®) in moderate-to-severe hidradenitis suppurativa (HS) continued to demonstrate sustained disease control and durable relief from key HS symptoms, including the potential to help prevent long-term structural damage caused by drai